- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
Research at a glance
Top areas of exploration
- Parkinson Disease , 43 publications
- Supranuclear Palsy, Progressive , 18 publications
- Multiple System Atrophy , 14 publications
- Parkinsonian Disorders , 13 publications
Research activity
Focus
Dr. McFarland is a member of the Norman Fixel Institute for Neurological Diseases and the Center for Translational Research in Neurodegenerative Disease (CTRND), which aims to bring the bench research closer to the bedside. His research focuses on understanding the pathological mechanisms of Parkinson disease and related disorders, and on identifying novel biomarkers for early detection and tracking of disease and therapeutic development. A primary goal of his research is to identify and to develop potential novel therapeutics for Parkinson disease and related disorders. His research extends also to the clinic where he is actively involved in multiple clinical trials for atypical Parkinson disorders and Huntington disease.
Active clinical trials
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease…
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 30 Years - N/A
- Sexes
- All
My publications
Filter publications
97 publications
2022
WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson's Disease Monocytes.
Frontiers in cellular neuroscience
•2021
A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study.
Movement disorders : official journal of the Movement Disorder Society
•2021
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.
Frontiers in neurology
•2021
Robust α-synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy.
Acta neuropathologica communications
•2021
Statistically Defined Parkinson's Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons.
Journal of Parkinson's disease
•